$470 Million is the total value of Ghost Tree Capital, LLC's 55 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TSRO | New | TESARO INC | $17,555,000 | – | 450,000 | +100.0% | 3.73% | – |
| MRTX | New | MIRATI THERAPEUTICS INCput | $14,130,000 | – | 300,000 | +100.0% | 3.00% | – |
| FXF | New | INVESCO CURNCYSHS SWISS FRANswiss franc | $12,266,000 | – | 128,700 | +100.0% | 2.61% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INCcall | $10,380,000 | – | 500,000 | +100.0% | 2.21% | – |
| RTRX | New | RETROPHIN INC | $10,056,000 | – | 350,000 | +100.0% | 2.14% | – |
| ZGNX | New | ZOGENIX INC | $9,920,000 | – | 200,000 | +100.0% | 2.11% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $7,989,000 | – | 300,000 | +100.0% | 1.70% | – |
| BHVN | New | BIOHAVEN PHARMACTL HLDG CO L | $7,510,000 | – | 200,000 | +100.0% | 1.60% | – |
| GBT | New | GLOBAL BLOOD THERAPEUTICS INcall | $5,700,000 | – | 150,000 | +100.0% | 1.21% | – |
| KALV | New | KALVISTA PHARMACEUTICALS INC | $4,975,000 | – | 225,000 | +100.0% | 1.06% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INCcall | $4,376,000 | – | 50,000 | +100.0% | 0.93% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS | $3,815,000 | – | 500,000 | +100.0% | 0.81% | – |
| UROV | New | UROVANT SCIENCES LTD | $3,600,000 | – | 300,000 | +100.0% | 0.76% | – |
| RDUS | New | RADIUS HEALTH INC | $3,560,000 | – | 200,000 | +100.0% | 0.76% | – |
| ALLK | New | ALLAKOS INC | $3,374,000 | – | 75,000 | +100.0% | 0.72% | – |
| ARVN | New | ARVINAS INC | $2,952,000 | – | 175,000 | +100.0% | 0.63% | – |
| AQXP | New | AQUINOX PHARMACEUTICALS INC | $1,465,000 | – | 500,000 | +100.0% | 0.31% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $1,342,000 | – | 9,500 | +100.0% | 0.28% | – |
| FATE | New | FATE THERAPEUTICS INC | $1,222,000 | – | 75,000 | +100.0% | 0.26% | – |
| GRTS | New | GRITSTONE ONCOLOGY INC | $1,068,000 | – | 75,000 | +100.0% | 0.23% | – |
| INSM | New | INSMED INC | $526,000 | – | 26,000 | +100.0% | 0.11% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2020-04-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 30 | Q3 2023 | 7.3% |
| ASCENDIS PHARMA A/S - ADR | 28 | Q3 2023 | 11.8% |
| BIOCRYST PHARMACEUTICALS INC | 25 | Q2 2023 | 2.4% |
| AMICUS THERAPEUTICS INC | 23 | Q3 2023 | 5.6% |
| SAREPTA THERAPEUTICS INC | 22 | Q3 2023 | 9.1% |
| SPDR SER TR | 20 | Q3 2022 | 16.9% |
| IOVANCE BIOTHERAPEUTICS INC | 18 | Q2 2023 | 5.5% |
| ROCKET PHARMACEUTICALS INC | 18 | Q2 2023 | 6.1% |
| SAGE THERAPEUTICS INC | 18 | Q1 2021 | 4.8% |
| IMMUNOMEDICS INC | 17 | Q2 2020 | 8.7% |
View Ghost Tree Capital, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-16 |
View Ghost Tree Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.